Agios Pharmaceuticals Inc. (AGIO) faces a key catalyst on September 7, 2025, when the FDA will decide whether to expand approval of its flagship drug, PYRUKYND.The company seeks regulatory clearance to expand the drug's label to include treatment of adult patients with all forms of alpha- and beta-thalassemia, regardless of whether they require blood transfusions.Thalassemia is an inherited blood ...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.